# US 2022/0031674 A1 · Compositions and methods for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031674 A1
- Document ID: US20220031674A1
- Status: Published application
- Kind: A1
- Application number: 16/945,323
- Filed: 2020-07-31
- Published: 2022-02-03
- Earliest claimed: 2020-07-31
- Assignees: University of Iowa Research Foundation
- Applicants: University of Iowa Research Foundation
- Inventors: Michael K. Schultz; Somya Kapoor; Douglas R. Spitz
- Web page: https://patentgrep.com/patent/US20220031674A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/66: Phosphorus compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/2818: {against CD28 or CD152}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

## Claims

### Claim 1

A combination of a glutathione (GSH) synthesis inhibitor and an anti-cancer composition comprising one or more anti-cancer agents for the therapeutic treatment of a hyperproliferative disorder.

### Claim 2 (depends on 1)

The combination of claim 1, wherein the hyperproliferative disorder is cancer.

### Claim 3 (depends on 2)

The combination of claim 2, wherein the cancer is drug-resistant.

### Claim 4 (depends on 2)

The combination of claim 2, wherein the cancer is melanoma.

### Claim 5 (depends on 1)

The combination of claim 1 wherein the one or more cancer agents are MAPK-pathway inhibitors (MAPKi).

### Claim 6 (depends on 1)

The combination of claim 1, wherein the hyperproliferative disorder is resistant to a MAPK-pathway inhibitor (MAPKi).

### Claim 7 (depends on 1)

The combination of claim 1, wherein the GSH synthesis inhibitor is administered simultaneously with the anti-cancer composition.

### Claim 8 (depends on 1)

The combination of claim 1, wherein the GSH synthesis inhibitor and the anti-cancer composition are administered sequentially.

### Claim 9 (depends on 1)

The combination of claim 1, wherein administration of the anti-cancer composition begins about 1 to about 10 days before administration of the GSH synthesis inhibitor.

### Claim 10 (depends on 1)

The combination of claim 1, wherein administration of the GSH synthesis inhibitor begins about 1 to about 10 days before administration of the anti-cancer composition.

### Claim 11 (depends on 1)

The combination of claim 1, wherein administration of the GSH synthesis inhibitor and administration of the anti-cancer composition begin on the same day.

### Claim 12 (depends on 1)

The combination of claim 1, wherein the GSH synthesis inhibitor is buthionine suloximine (BSO).

### Claim 13 (depends on 1)

The combination of claim 1, wherein the anti-cancer composition comprises vemurafenib.

### Claim 14 (depends on 13)

The combination of claim 13, wherein the anti-cancer composition further comprises cobimetinib.

### Claim 15 (depends on 1)

The combination of claim 1, wherein the anti-cancer composition comprises a derivative of triphenylphosphonium (TPP).

### Claim 16 (depends on 1)

The combination of claim 1, wherein the anti-cancer composition comprises ipilimumab.

### Claim 17 (depends on 1)

The combination of claim 1, wherein the GSH synthesis inhibitor is administered in combination with vemurafenib, and the cancer is melanoma.

### Claim 18 (depends on 1)

The combination of claim 1, wherein GSH synthesis inhibitor is administered in combination with vemurafenib and cobimetinib, and the cancer is melanoma.

### Claim 19

A kit comprising a GSH synthesis inhibitor, a container, and a package insert or label indicating the administration of the GSH synthesis inhibitor with an anti-cancer composition for treating a hyperproliferative disorder.

### Claim 20

A method for treating a hyperproliferative disorder in a mammal, comprising administering to the mammal a combination of a GSH synthesis inhibitor and an anti-cancer composition.
